Medical advancements continue to enhance targeted therapies for IDH2 mutations. Enasidenib Tablets in India are designed to inhibit mutant IDH2 enzymes, supporting normal cell function and metabolic balance. This innovative approach contributes to ongoing oncology research. Impomed Healthcare remains dedicated to providing advanced solutions, ensuring progress in scientific studies and the development of effective targeted treatments. For more information visit: https://www.impomedhealthcare.com